Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease
- Katsutoshi Sato
- Amol A. Padgaonkar
- Stacey J. Baker
- Stephen C. Cosenza
- Olga Rechkoblit
- D. R. C. Venkata Subbaiah
- Josep Domingo-Domenech
- Alison Bartkowski
- Elisa R. Port
- Aneel K. Aggarwal
- M. V. Ramana Reddy
- Hanna Y. Irie
- E. Premkumar Reddy
Publication date
August 2021
DOI Publisher
Springer Science and Business Media LLC Journal
Nature CommunicationsAbstract
Finding therapeutic strategies for aggressive triple negative breast cancer (TNBC) is an important challenge in clinical practice. Here, the authors identify a multi-kinases inhibitor with antitumor activity and able overcome chemotherapy resistance of TNBC in vivo
Add to ORKG